On the one hand it's a $1 billion market cap for a company with not one product in phase III trials so that's not good. On the other hand there's a lot of potential and insiders are buying like mad. Not sure I've ever seen insiders buy this much stock so quickly. Of course the wildcard factor is the wild and crazy stock market. Any thoughts?